全文获取类型
收费全文 | 39173篇 |
免费 | 2628篇 |
国内免费 | 97篇 |
专业分类
耳鼻咽喉 | 449篇 |
儿科学 | 1446篇 |
妇产科学 | 950篇 |
基础医学 | 4895篇 |
口腔科学 | 466篇 |
临床医学 | 6479篇 |
内科学 | 6785篇 |
皮肤病学 | 543篇 |
神经病学 | 3734篇 |
特种医学 | 803篇 |
外国民族医学 | 1篇 |
外科学 | 3598篇 |
综合类 | 363篇 |
一般理论 | 49篇 |
预防医学 | 5519篇 |
眼科学 | 404篇 |
药学 | 2378篇 |
中国医学 | 45篇 |
肿瘤学 | 2991篇 |
出版年
2024年 | 30篇 |
2023年 | 331篇 |
2022年 | 454篇 |
2021年 | 863篇 |
2020年 | 612篇 |
2019年 | 953篇 |
2018年 | 1105篇 |
2017年 | 820篇 |
2016年 | 870篇 |
2015年 | 957篇 |
2014年 | 1341篇 |
2013年 | 2121篇 |
2012年 | 3061篇 |
2011年 | 3247篇 |
2010年 | 1732篇 |
2009年 | 1568篇 |
2008年 | 2806篇 |
2007年 | 2820篇 |
2006年 | 2754篇 |
2005年 | 2699篇 |
2004年 | 2486篇 |
2003年 | 2210篇 |
2002年 | 2127篇 |
2001年 | 245篇 |
2000年 | 213篇 |
1999年 | 272篇 |
1998年 | 441篇 |
1997年 | 342篇 |
1996年 | 263篇 |
1995年 | 213篇 |
1994年 | 220篇 |
1993年 | 217篇 |
1992年 | 133篇 |
1991年 | 117篇 |
1990年 | 94篇 |
1989年 | 103篇 |
1988年 | 94篇 |
1987年 | 80篇 |
1986年 | 83篇 |
1985年 | 84篇 |
1984年 | 102篇 |
1983年 | 79篇 |
1982年 | 91篇 |
1981年 | 102篇 |
1980年 | 71篇 |
1979年 | 46篇 |
1978年 | 31篇 |
1977年 | 43篇 |
1976年 | 22篇 |
1975年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
2.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract
Purpose
Financial hardship can be a major cause of distress among persons with cancer, resulting in chronic stress and impacting physical and emotional health. This paper provides an analysis of the lived experience of cancer patients’ financial hardship from diagnosis to post-treatment. 相似文献3.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献4.
5.
6.
7.
8.
Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung?
下载免费PDF全文
![点击此处可从《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kim Hein Lindahl Flemming Brandt Sørensen Søren Peter Jonstrup Karen Ege Olsen Siegfried Loeschke 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(4):289-297
The identification of EGFR mutations in non‐small‐cell lung cancer is important for selecting patients, who may benefit from treatment with EGFR tyrosine kinase inhibitors. The analysis is usually performed on cytological aspirates and/or histological needle biopsies, representing a small fraction of the tumour volume. The aim of the present investigation was to evaluate the diagnostic performance of this molecular test. We retrospectively included 201 patients with primary adenocarcinoma of the lung. EGFR mutation status (exon 19 deletions and exon 21 L858R point mutation) was evaluated on both pre‐operative biopsies (131 histological and 70 cytological) and on the surgical specimens, using PCR. Samples with low tumour cell fraction were assigned to laser micro‐dissection (LMD). We found nine (4.5%) patients with EGFR mutation in the lung tumour resections, but failed to identify mutation in one of the corresponding pre‐operative, cytological specimens. Several (18.4%) analyses of the pre‐operative biopsies were inconclusive, especially in case of biopsies undergoing LMD and regarding exon 21 analysis. Discrepancy of mutation status in one patient may reflect intra‐tumoural heterogeneity or technical issues. Moreover, several inconclusive results in the diagnostic biopsies reveal that attention must be paid on the suitability of pre‐operative biopsies for EGFR mutation analysis. 相似文献
9.
10.